[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours (Q39239023)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 November 2012

Language	Label	Description	Also known as
English	[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours	scientific article published on 21 November 2012

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours (English)

1 reference

Europe PubMed Central

10 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Anna Orlova

1

1 reference

Europe PubMed Central

10 September 2017

Camilla Hofström

2

1 reference

Europe PubMed Central

10 September 2017

Joanna Strand

3

1 reference

Europe PubMed Central

10 September 2017

Zohreh Varasteh

4

1 reference

Europe PubMed Central

10 September 2017

Mattias Sandstrom

5

1 reference

Europe PubMed Central

10 September 2017

Karl Andersson

6

1 reference

Europe PubMed Central

10 September 2017

Vladimir Tolmachev

7

1 reference

Europe PubMed Central

10 September 2017

Torbjörn Gräslund

8

1 reference

Europe PubMed Central

10 September 2017

publication date

21 November 2012

1 reference

Europe PubMed Central

10 September 2017

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

10 September 2017

40

1 reference

Europe PubMed Central

10 September 2017

3

1 reference

Europe PubMed Central

10 September 2017

439-449

1 reference

Europe PubMed Central

10 September 2017

https://scigraph.springernature.com/pub.10.1007/s00259-012-2284-8

0 references

Insulin-like growth factors and neoplasia.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Targeting the IGF1 axis in cancer proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

IGF-1 receptor inhibitors in clinical trials--early lessons

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Defining the pathway to insulin-like growth factor system targeting in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Radionuclide molecular imaging using Affibody molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Immuno-PET: a navigator in monoclonal antibody development and applications.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

An Investigation of the Ligand Binding Properties and Negative Cooperativity of Soluble Insulin-like Growth Factor Receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2284-8

21 January 2018

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23179942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/23179942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23179942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/23179942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/23179942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-012-2284-8

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39239023&oldid=1815306814"